Harrow Expands Vevye Access for All Program to Klarity-C Patients

Harrow has announced the expansion of its Vevye Access for All (VAFA) program, now extending eligibility to patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% ophthalmic product manufactured by Harrow’s compounding pharmacy subsidiary, ImprimisRx.

Broadening Access to FDA-Approved Dry Eye Treatment

Initially launched on March 17, 2025, the VAFA program was developed to simplify access to dry eye therapy by removing traditional barriers such as prior authorizations and insurance reimbursement delays. The program includes features such as:

       • Free home delivery

       • A no-questions-asked money-back guarantee

       • The option for patients to use insurance or pay a low, transparent cash price

With this expansion, more than 25,000 Klarity-C patients across the U.S. are now eligible to switch to Vevye (cyclosporine ophthalmic solution 0.1%), an FDA-approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle, including refills.

Streamlined Prescription Transfers for Prescribers

To facilitate the transition, Harrow has introduced a 5-minute prescription authorization platform, allowing eye care professionals to quickly and efficiently transfer Klarity-C prescriptions to PhilRx, the pharmacy fulfillment partner. This technology is intended to reduce administrative burden for prescribers and accelerate patient access.

Leadership Perspective

Mark L. Baum, Chief Executive Officer of Harrow, commented on the program's growth and its impact on patient care:

“We are pleased to make Vevye accessible and affordable to Klarity-C patients. The secret to the success of Vevye Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy.”